Analyst Price Target is $87.15
▲ +215.66% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $87.15, with a high forecast of $138.00 and a low forecast of $30.00. The average price target represents a 215.66% upside from the last price of $27.61.
Current Consensus is
Buy
The current consensus among 14 polled investment analysts is to buy stock in Viking Therapeutics. This rating changed within the last month from a Moderate Buy consensus rating.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Read More
